Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Vir Biotechnology announces that CFO Howard Horn will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vir Biotechnology announces that CFO Howard Horn will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 a.m. PT / 7:00 a.m. ET. The presentation will be available via live webcast on the company's website and archived for 30 days.
Vir focuses on leveraging immunologic insights and technology to combat infectious diseases, with a development pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Details
News Market Reaction – VIR
The recorded move for VIR in the trading session of this news was -1.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET.
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.
The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investors website, in addition to following the Company’s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.